Maze Therapeutics (MAZE) Net Income towards Common Stockholders (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Net Income towards Common Stockholders data on file, last reported at -$19.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 40.23% year-over-year to -$19.6 million; the trailing twelve-month figure through Mar 2026 stood at -$90.4 million (down 315.65% YoY), and the FY2025 full-year result was -$131.1 million, down 3950.81% from the prior year.
• Net Income towards Common Stockholders retreated to -$19.6 million in Q1 2026, from -$7.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $139.1 million in Q2 2024 to a low of -$39.6 million in Q4 2024.
• A 3-year average of -$8.5 million and a median of -$27.7 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 82.25% in 2025, while the deepest fall reached 124.22% in 2025.
• Tracing MAZE's Net Income towards Common Stockholders over 3 years: stood at -$39.6 million in 2024, then soared by 82.25% to -$7.0 million in 2025, then tumbled by 178.62% to -$19.6 million in 2026.
• Business Quant data shows MAZE's Net Income towards Common Stockholders at -$19.6 million in Q1 2026, -$7.0 million in Q4 2025, and -$30.1 million in Q3 2025.